Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of MK-3120 in advanced solid tumors
CTR20251708Phase 2Active
- Sponsor
- MSD
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MK-3120 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), transitional cell carcinoma (TCC), cholangiocarcinoma (CCA), sponsored by MSD. Started May 2025; status: active.
02
Drugs
MK-3120
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on CTR20251708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251708.